Oleclumab

Generic Name
Oleclumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1803176-05-7
Unique Ingredient Identifier
5CRY01URYQ
Background

Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

Phase 2
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Oleclumab
Drug: Durvalumab
First Posted Date
2024-09-23
Last Posted Date
2024-11-27
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT06606847
Locations
🇷🇺

Research Site, Ufa, Russian Federation

Durvalumab and Oleclumab in Resectable PDAC

First Posted Date
2023-09-29
Last Posted Date
2024-01-08
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
22
Registration Number
NCT06060405
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

First Posted Date
2022-02-03
Last Posted Date
2024-12-09
Lead Sponsor
AstraZeneca
Target Recruit Count
999
Registration Number
NCT05221840
Locations
🇻🇳

Research Site, Ho Chi Minh, Vietnam

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

First Posted Date
2021-09-29
Last Posted Date
2024-12-19
Lead Sponsor
AstraZeneca
Target Recruit Count
630
Registration Number
NCT05061550
Locations
🇹🇷

Research Site, Izmir, Turkey

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

First Posted Date
2021-06-25
Last Posted Date
2024-11-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
13
Registration Number
NCT04940286
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

First Posted Date
2020-12-16
Last Posted Date
2024-11-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
75
Registration Number
NCT04668300
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

First Posted Date
2019-09-13
Last Posted Date
2024-04-16
Lead Sponsor
AstraZeneca
Target Recruit Count
59
Registration Number
NCT04089553
Locations
🇺🇸

Research Site, Nashville, Tennessee, United States

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

First Posted Date
2019-08-28
Last Posted Date
2023-11-15
Lead Sponsor
MedImmune LLC
Target Recruit Count
61
Registration Number
NCT04068610
Locations
🇪🇸

Research Site, Madrid, Spain

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

First Posted Date
2019-03-14
Last Posted Date
2024-12-20
Lead Sponsor
Jules Bordet Institute
Target Recruit Count
147
Registration Number
NCT03875573
Locations
🇧🇪

Universitaire Ziekenhuizen, Leuven, Belgium

🇧🇪

Institut Jules Bordet, Bruxelles, Belgium

🇧🇪

Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

and more 4 locations

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

First Posted Date
2019-01-28
Last Posted Date
2024-10-22
Lead Sponsor
AstraZeneca
Target Recruit Count
175
Registration Number
NCT03819465
Locations
🇹🇭

Research Site, Hat Yai, Thailand

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy